论文部分内容阅读
目的:探讨阿莫西林克拉维酸钾在治疗小儿肺炎的临床疗效。方法:选择2016年1月至10月我院儿科88例被确诊为肺炎的患儿随机分为2组,研究组患儿接受阿莫西林克拉维酸钾治疗,对照组患儿接受头孢呋辛治疗,观察并统计2组患儿临床治疗效果,记录患儿药物不良反应发生情况。结果:研究组患儿经过治疗后,其临床治疗效果(95.45%)显著优于对照组(81.82%),且其药物不良反应发生率(2.27%)显著低于对照组(15.91%),p<0.05。结论:在临床小儿肺炎的治疗中使用阿莫西林克拉维酸钾进行治疗,可明显提高患儿治愈率,疗效显著,且药物副反应较少,安全性较高,值得临床推广。
Objective: To investigate the clinical efficacy of amoxicillin and clavulanate potassium in the treatment of children pneumonia. Methods: From January to October 2016, 88 children with pneumonia diagnosed as pneumonia in our hospital were randomly divided into two groups. The study group received amoxicillin-treated potassium clavulanate and the control group received cefuroxime Treatment, observation and statistics of two groups of children with clinical treatment, record of children with adverse drug reactions. Results: After treatment, the clinical efficacy (95.45%) of the study group was significantly better than that of the control group (81.82%), and the incidence of adverse drug reactions (2.27%) was significantly lower than that of the control group (15.91%). <0.05. Conclusion: The treatment of amloxicillin and clavulanate in clinical pediatric pneumonia treatment can significantly improve the cure rate of children with significant curative effect, less side effects and high safety, which is worthy of clinical promotion.